These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

724 related articles for article (PubMed ID: 27893147)

  • 1. Update on the Pharmacology and Legal Status of Kratom.
    Prozialeck WC
    J Am Osteopath Assoc; 2016 Dec; 116(12):802-809. PubMed ID: 27893147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kratom policy: The challenge of balancing therapeutic potential with public safety.
    Prozialeck WC; Avery BA; Boyer EW; Grundmann O; Henningfield JE; Kruegel AC; McMahon LR; McCurdy CR; Swogger MT; Veltri CA; Singh D
    Int J Drug Policy; 2019 Aug; 70():70-77. PubMed ID: 31103778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects.
    Prozialeck WC; Jivan JK; Andurkar SV
    J Am Osteopath Assoc; 2012 Dec; 112(12):792-9. PubMed ID: 23212430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changing trends in the use of kratom (Mitragyna speciosa) in Southeast Asia.
    Singh D; Narayanan S; Vicknasingam B; Corazza O; Santacroce R; Roman-Urrestarazu A
    Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28544011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns and reasons for kratom (Mitragyna speciosa) use among current and former opioid poly-drug users.
    Singh D; Yeou Chear NJ; Narayanan S; Leon F; Sharma A; McCurdy CR; Avery BA; Balasingam V
    J Ethnopharmacol; 2020 Mar; 249():112462. PubMed ID: 31816368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kratom: a primer for pain physicians.
    Emerick T; Durbhakula S; Eibel MR; Kohan L
    Curr Opin Anaesthesiol; 2024 Oct; 37(5):575-580. PubMed ID: 39011659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The abuse potential of kratom according the 8 factors of the controlled substances act: implications for regulation and research.
    Henningfield JE; Fant RV; Wang DW
    Psychopharmacology (Berl); 2018 Feb; 235(2):573-589. PubMed ID: 29273821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mini review: Potential therapeutic values of mitragynine as an opioid substitution therapy.
    Harun N; Kamaruzaman NA; Mohamed Sofian Z; Hassan Z
    Neurosci Lett; 2022 Mar; 773():136500. PubMed ID: 35114335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacology and toxicology of kratom: from traditional herb to drug of abuse.
    Warner ML; Kaufman NC; Grundmann O
    Int J Legal Med; 2016 Jan; 130(1):127-38. PubMed ID: 26511390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kratom: Substance of Abuse or Therapeutic Plant?
    Gorelick DA
    Psychiatr Clin North Am; 2022 Sep; 45(3):415-430. PubMed ID: 36055730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Pharmacokinetics of Mitragynine after Oral Administration of Mitragyna speciosa (Kratom) Leaf Extracts in Rats.
    Avery BA; Boddu SP; Sharma A; Furr EB; Leon F; Cutler SJ; McCurdy CR
    Planta Med; 2019 Mar; 85(4):340-346. PubMed ID: 30452072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Pharmacology of the Dietary Supplement Kratom (Mitragyna speciosa).
    Hartley C; Bulloch M; Penzak SR
    J Clin Pharmacol; 2022 May; 62(5):577-593. PubMed ID: 34775626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kratom (Mitragyna speciosa): Friend or Foe?
    Sethi R; Hoang N; Ravishankar DA; McCracken M; Manzardo AM
    Prim Care Companion CNS Disord; 2020 Jan; 22(1):. PubMed ID: 31999896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A validated method for the quantification of mitragynine in sixteen commercially available Kratom (Mitragyna speciosa) products.
    Fowble KL; Musah RA
    Forensic Sci Int; 2019 Jun; 299():195-202. PubMed ID: 31059866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic and clinical assessment of kratom: An update.
    White CM
    Am J Health Syst Pharm; 2019 Nov; 76(23):1915-1925. PubMed ID: 31626272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic and clinical assessment of kratom.
    White CM
    Am J Health Syst Pharm; 2018 Mar; 75(5):261-267. PubMed ID: 29255059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From Kratom to mitragynine and its derivatives: physiological and behavioural effects related to use, abuse, and addiction.
    Hassan Z; Muzaimi M; Navaratnam V; Yusoff NH; Suhaimi FW; Vadivelu R; Vicknasingam BK; Amato D; von Hörsten S; Ismail NI; Jayabalan N; Hazim AI; Mansor SM; Müller CP
    Neurosci Biobehav Rev; 2013 Feb; 37(2):138-51. PubMed ID: 23206666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Self-reported prevalence and severity of opioid and kratom (Mitragyna speciosa korth.) side effects.
    Saref A; Suraya S; Singh D; Grundmann O; Narayanan S; Swogger MT; Prozialeck WC; Boyer E; Chear NJY; Balasingam V
    J Ethnopharmacol; 2019 Jun; 238():111876. PubMed ID: 31014959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurobiology of Kratom and its main alkaloid mitragynine.
    Suhaimi FW; Yusoff NH; Hassan R; Mansor SM; Navaratnam V; Müller CP; Hassan Z
    Brain Res Bull; 2016 Sep; 126(Pt 1):29-40. PubMed ID: 27018165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemical composition and biological effects of kratom (Mitragyna speciosa): In vitro studies with implications for efficacy and drug interactions.
    Todd DA; Kellogg JJ; Wallace ED; Khin M; Flores-Bocanegra L; Tanna RS; McIntosh S; Raja HA; Graf TN; Hemby SE; Paine MF; Oberlies NH; Cech NB
    Sci Rep; 2020 Nov; 10(1):19158. PubMed ID: 33154449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.